Summit
SPECULATIVE BUYDays after announcing record losses, drug developer Summit has sealed a licensing deal worth up to $143m (£72m) for one of its pre-clinical candidates.
This is an important deal for Summit, known until last year as VASTox, whose valuation halved in the last two years as the market began to doubt its original assessment. Recent results cast the shares even lower as the Oxfordshire-based company unveiled losses had trebled in the year to January as it geared up R&D.
However Summit’s model is an interesting one as it has two technology platforms, zebrafish and carbohydrate chemistry, that both perform the similar dual function of generating cash as service providers and enabling the company to discover its own drugs. Thus there are five drug candidates on the roster, three at the pre-clinical stage and two in clinical trials.
After signing a £10m collaboration last year with Swiss company Evolva for a treatment that emerged from its carbohydrate chemistry platform, Summit’s has now secured a much bigger deal. US biopharma Bi0Marin has bought the worldwide licence to develop and commercialise the compound C1100 for the treatment of Duchenne’s muscular dystrophy for $143m.
This involves an immediate $7m equity investment and, says Summit’s chief executive Steve Lee, ‘by early next year we could trigger $4m with another $50m in the next three years at no extra cost to us.’ With BioMarin absorbing some development costs, house broker Panmure predicts R&D spend in each of the next two years will be £2m lower.
With £10m cash in the bank at year end and the management’s strategy proven, Lee’s hopes to sign deals for other drugs or even a collaboration on the entire carbohydrates platform have gained weight. Less than half their 135p listing price, the shares look unfairly undervalued. Speculative buy.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £32.03m
PE Forecast: n/a
Share price: 63p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
GW Pharmaceuticals 31/08/2010
GW Pharmaceuticals has won approval from Health Canada for its cannabis-based Sativex product to treat spasticity caused by Multiple Sclerosis.
Sectors
